Drug Profile
Tyrosine kinase 2 inhibitor - Bristol-Myers Squibb
Alternative Names: TYK2 inhibitor - Bristol-Myers SquibbLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Cutaneous lupus erythematosus
Most Recent Events
- 23 Feb 2022 Phase I development is ongoing in USA (Bristol Myers Squibb pipeline, February 2022)
- 23 Feb 2022 Phase-I clinical trials in Cutaneous lupus erythematosus in USA (Bristol Myers Squibb pipeline, February 2022)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA